Because of the dearth of targeted treatments in China, patients with relapsed/refractory (R/R) NHL, multiple myeloma, or ALL continue to be prescribed salvage chemotherapy in later lines of treatment. Ongoing reforms in China’s regulatory landscape, such as breakthrough therapy designation and priority review pathway, are encouraging domestic and international companies to develop innovative treatments such as CAR T-cell therapies for R/R patients. Many such therapies are in clinical trials in China, and some—such as axicabtagene ciloleucel (Fosun Kite’s Yescarta), tisagenlecleucel (Novartis’s Kymriah), and JWCAR029 (JW Therapeutics)—are expected to launch there in the next few years. We anticipate that China will become a market leader in CAR T-cell therapies during the forecast period.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 hematologist-oncologists.
Diagnosed incidence of non-Hodgkin’s lymphoma, multiple myeloma, and acute lymphoblastic leukemia in urban versus rural China. Clinically relevant and market-relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient share of key CAR T-cell therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 3 drugs; Phase II: 3 drugs; coverage of select preclinical and Phase I products.